This is a must-watch. Thanks Eire.
* Excellent anecdotally observed results from SAVR, especially in valve area, which is essentially the same as a healthy natural heart valve.
* TAVR study progressing on track.
* Bench-test valve has passed 500M, roughly equating to more than a decade of use in humans, with no deterioration.
* New 3D ADAPT product for heart by-passes, currently being tested. No real alternative available in a huge market.
* Several completed tests (already disclosed) showing ADAPT tissue strongly superior to competitors in its non-calcification properties.
* Current calcification study to report later this year.
* Market is competitive, with two major players, but liable to turn quickly in favour of a clinically superior product.
* No obvious competitive disruptive technology on the horizon.
* Strong news-flow for the next 18 months to 2 years.
IMHO, the competitive advantage of the ADAPT intellectual property is the gunpowder in this stock.
DYOR and listen to the interview.
- Forums
- ASX - By Stock
- Interview with CEO Wayne Paterson re: 2020 milestones
This is a must-watch. Thanks Eire.* Excellent anecdotally...
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.65 |
Change
-0.060(0.38%) |
Mkt cap ! $300.8M |
Open | High | Low | Value | Volume |
$15.72 | $15.85 | $15.51 | $1.660M | 117.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 312 | $15.51 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.65 | 626 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 312 | 15.510 |
1 | 650 | 15.500 |
1 | 646 | 15.490 |
1 | 6 | 15.450 |
1 | 50 | 15.400 |
Price($) | Vol. | No. |
---|---|---|
15.880 | 250 | 1 |
16.000 | 134 | 1 |
16.200 | 200 | 1 |
16.250 | 1000 | 1 |
16.500 | 1034 | 2 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |